Organogenesis Holdings Inc. ORGO
Regular-session close
After hours · Nov 16, 4:00 PM ET
- YTD
- -84.50%
- 1 year
- -86.83%
- Market cap
- 104.24M
- Revenue (ttm)
- 455.04M
- Profit margin
- -1.62%
- EPS (ttm)
- -1.19
- Shares out
- 125.73M
- Forward P/E
- -79.50
- YTD return
- -84.50%
- 1-year return
- -86.83%
- 50-day average
- 3.44
- Volume
- 934.87K
- Avg volume
- 838.39K
- Open
- 0.81
- Previous close
- 0.8101
- Day's range
- 0.7817 – 0.8368
- 52-week range
- 0.73 – 6.20
- Beta
- 1.60
- Analysts
- Strong Buy
- Price target
- 5.00 (+522.6%)
5D +0.1668 (+20.45%)
Key statistics
- 200-day average
- 2.93
- Enterprise value
- 417.69M
- Price / sales
- 0.88
- Price / book
- 1.51
- Revenue growth
- 6.10%
- Free cash flow
- 13.47M
- Total cash
- 94.34M
- Total debt
- 107.67M
- Return on equity
- -2.66%
- Short % of float
- 23.88%
Fundamental scorecard
6 of 25 checks passed on ORGO’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.02 | 0.09 | +0.11 | +550.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.02 | -0.13 | -0.11 | -550.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.02 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.03 | -0.02 | +0.01 | +33.33% |
| May 9, 2024 | Mar 1, 2024 | -0.03 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.01 | 0.00 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 28, 2024 | Lake Street | init | — | Buy |
| Mar 1, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Feb 7, 2024 | Cantor Fitzgerald | init | — | Overweight |
| Dec 27, 2023 | BTIG | main | Buy | Buy |
| Nov 14, 2023 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Aug 11, 2023 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- organogenesis.com
News
Organogenesis Holdings Q3 2026 Earnings Call Transcript Organogenesis Hldgs Q3 Adj. EPS $(0.25) Misses $(0.17) Estimate, Sales $45.457M Miss $52.100M Estimate
Organogenesis Holdings Narrows FY2026 Sales Guidance from $179.000M-$215.000M to $179.400M-$200.000M vs $196.050M Est
12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on ORGO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BILBO PATRICK | Chief Operating Officer | Conversion of Exercise of derivative security | Mar 27, 2024 | 811,579 |
| DRISCOLL MICHAEL JOSEPH | Director | Stock Award(Grant) | Feb 20, 2024 | 142,304 |
| DURAIBABU PRATHYUSHA | Director | Stock Award(Grant) | Feb 20, 2024 | 148,644 |
| FRANCISCO DAVID | Chief Financial Officer | Stock Award(Grant) | Feb 20, 2024 | 428,996 |
| FREEDMAN LORI | Officer | Stock Award(Grant) | Feb 20, 2024 | 471,246 |
| GILLHEENEY GARY S. SR. | Chief Executive Officer | Sale | Dec 15, 2024 | 3,039,190 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 9.52% | 11,969,734 | 38.06M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 9.42% | 11,839,876 | 37.65M | Sep 29, 2024 |
| Blackrock Inc. | 4.24% | 5,329,412 | 16.95M | Sep 29, 2024 |
| Deutsche Bank Aktiengesellschaft | 3.85% | 4,843,692 | 15.40M | Sep 29, 2024 |
| Vanguard Group Inc | 2.92% | 3,672,432 | 11.68M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 2.40% | 3,019,048 | 9.60M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.54% | 1,936,093 | 6.16M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.26% | 1,588,928 | 5.05M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.87% | 1,099,012 | 3.49M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.59% | 739,764 | 2.35M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.48% | 607,510 | 1.93M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 422,095 | 1.34M | Oct 30, 2024 |
